NVO vs VTVT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and VTVT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and VTVT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

vTv Therapeutics is a clinical-stage biopharmaceutical company, meaning it has no approved products and no meaningful product revenue; its value rests on the potential of drug candidates still in testing. Its lead program is cadisegliatin (previously known as TTP399), an oral small-molecule, liver-selective glucokinase activator being developed as a potential first-in-class oral adjunctive treatment for type 1 diabetes, taken alongside insulin. The drug produced positive Phase 2 results (the Simplici-T1 study) showing improvements in blood-sugar control and time in range, and it has been granted Breakthrough Therapy designation by the FDA, a status meant to speed development of promising therapies. It is now being evaluated in a US Phase 3 trial, CATT1, with enrollment expected to complete in the second half of 2026.

Full VTVT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
• VTVT drivers: Cadisegliatin Phase 3 in type 1 diabetes; Cash runway and non-dilutive funding.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. For VTVT, the overriding risk is binary clinical and regulatory failure: as a pre-revenue micro-cap, vTv's value depends on a small number of drug candidates, and a disappointing CATT1 result or an FDA setback could sharply cut the stock.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVO if you believe its drivers more; VTVT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and VTVT guides.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

VTVT. Figures are approximate and tied to the asOf date; verify live numbers (current cash, burn rate, market cap, share count, and CATT1 trial timing) before acting. Standard valuation metrics like P/E do not meaningfully apply to a pre-revenue biotech; the stock is valued on the probability-weighted potential of its pipeline. Any occasional reported quarterly profit is usually driven by one-off licensing income rather than a sustainable business, so cash runway and trial milestones matter far more than reported earnings.

Headline figures (approximate, early 2026): NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate); VTVT shows stage Clinical-stage biotech; no approved products and no meaningful product revenue, market cap Micro-cap, roughly in the low hundreds of millions of dollars (varies sharply with trial news), lead program Cadisegliatin (TTP399), oral glucokinase activator, in the CATT1 Phase 3 trial for type 1 diabetes; FDA Breakthrough Therapy designation, cash position ~$98 million as of Q1 2026, aided by a $20 million Newsoara upfront; described as sufficient toward CATT1 topline data.

NVO and VTVT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and VTVT exposure against your real portfolio. It is not an investment adviser.